<DOC>
	<DOCNO>NCT01288131</DOCNO>
	<brief_summary>Recombinant human erythropoietin ( r-HuEpo ) use treat renal anemia improve morbidity mortality chronic kidney disease . Subcutaneous use r-HuEpo cause immunogenicity develop anti-r-HuEpo associated pure red cell aplasia ( PRCA ) . The treatment anti-r-HuEpo associated pure red cell aplasia controversial . The investigator aim evaluate treatment anti-r-HuEpo associated pure red cell aplasia study .</brief_summary>
	<brief_title>Study Anti-r-HuEpo Associated Pure Red Cell Aplasia ( PRCA ) Treatment</brief_title>
	<detailed_description>Recombinant human erythropoietin first biotherapeutic medicinal product derive recombinant DNA technology treatment anemia patient chronic kidney disease ( CKD ) . Although r-HuEpo raise hemoglobin level CKD improve morbidity associate anemia CKD patient , adverse immunological effect r-HuEpo administer subcutaneously result anti-r-HuEpo associate PRCA . We aim evaluate effectiveness two treatment protocol , cyclosporine combine mycophenolate mofetil cyclophosphamide combine prednisolone treatment anti-r-HuEpo associate PRCA .</detailed_description>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Age 18 year old CKD patient antirhuEpo associate PRCA Pregnancy lactate woman Receiving immunosuppression Active infection Previous history allergic reaction cyclosporine , mycophenolate mofetil , cyclophosphamide , prednisolone</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Anti-r-HuEpo antibody</keyword>
	<keyword>Anti-r-HuEpo associate PRCA</keyword>
	<keyword>Treatment</keyword>
	<keyword>Absolute reticulocyte count</keyword>
</DOC>